Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 10/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | BRAF | P15056 | 2/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | KRAS | P01116 | 1/20 | 0.79 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | RET | P07949 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | ARAF | P10398 | 1/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.79 |
| ▸ | FECH | P22830 | 1/20 | 0.79 |
| ▸ | KDR | P35968 | 1/20 | 0.79 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298115 | 1.00 | CYP2C19 (0.83) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL7874949 | 0.94 | CYP2C9 (0.78) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL2163605 | 0.91 | CYP2C19 (0.80) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL298253 | 0.91 | CYP2C9 (0.71) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL297529 | 0.91 | BRAF (0.83) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL299487 | 0.91 | CYP2C19 (1.00) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL293377 | 0.91 | CYP2C19 (1.00) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL298392 | 0.91 | CYP2C9 (0.81) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL297952 | 0.90 | CYP2C19 (0.79) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF | |
| SCHEMBL720593 | 0.90 | CYP2C19 (0.82) | CYP2C19CYP2D6CYP2C9CYP3A4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP2C19 1536/4885CYP2D6 349/4885CYP2C9 871/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP2C19 1536/4885CYP2D6 349/4885CYP2C9 871/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP2C19 1536/4885CYP2D6 349/4885CYP2C9 871/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | CYP2C19 4082/4885CYP2D6 2582/4885CYP2C9 4092/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP2C19 1536/4885CYP2D6 349/4885CYP2C9 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.